Literature DB >> 19050931

Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene.

Laura Alías1, Sara Bernal, Pablo Fuentes-Prior, María Jesus Barceló, Eva Also, Rebeca Martínez-Hernández, Francisco J Rodríguez-Alvarez, Yolanda Martín, Elena Aller, Elena Grau, Ana Peciña, Guillermo Antiñolo, Enrique Galán, Alberto L Rosa, Miguel Fernández-Burriel, Salud Borrego, José M Millán, Concepción Hernández-Chico, Montserrat Baiget, Eduardo F Tizzano.   

Abstract

Spinal muscular atrophy (SMA) is caused by mutations in the SMN1 gene. We have studied the molecular pathology of SMA in 745 unrelated Spanish patients using PCR-RFLP, SMN gene dosage analysis, linkage studies, long-range PCR and direct sequencing. Our systematic approach allowed us to complete genetic testing and risk assessment in 736 SMA patients (98.8%). Females were more frequently affected by the acute form of the disease (type I), whereas chronic forms (type II-III) predominated in males (p<0.008). Absence of the SMN1 gene was detected in 671 patients (90%), and hybrid SMN1-SMN2 genes were observed in 37 cases (5%). Furthermore, we detected 13 small mutations in 28 patients (3.8%), four of which were previously identified in other populations (c.91dupT; c.770_780dup11; p.Tyr272Cys and p.Thr274Ile), while five mutations were found to date only in Spanish patients (c.399_402delAGAG, p.Ile116Phe, p.Gln136Glu, c.740dupC and c.834+2T>G). The c.399_402delAGAG mutation accounted for 1.9% of all Spanish SMA patients. Finally, we discovered four novel mutations: c.312dupA, c.411delT, p.Trp190X and p.Met263Thr. Our results confirm that most SMA cases are due to large genetic rearrangements in the repetitive region of the SMA locus, resulting in absence-dysfunction of the SMN1 gene. By contrast, ancestrally inherited small mutations are responsible for only a small number of cases. Four prevalent changes in exons 3 and 6 (c.399_402delAGAG; c.770_780dup11; p.Tyr272Cys; p.Thr274Ile) accounted for almost 70% of our patients with these subtle mutations. An SMN-SMN dimer model featuring tight hydrophobic-aromatic interactions is proposed to explain the impact of mutations at the C-terminal end of the protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050931     DOI: 10.1007/s00439-008-0598-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  51 in total

1.  Characterisation of SMN hybrid genes in Spanish SMA patients: de novo, homozygous and compound heterozygous cases.

Authors:  I Cuscó; M J Barceló; E del Rio; Y Martín; C Hernández-Chico; E Bussaglia; M Baiget; E F Tizzano
Journal:  Hum Genet       Date:  2001-03       Impact factor: 4.132

2.  International SMA consortium meeting. (26-28 June 1992, Bonn, Germany).

Authors:  T L Munsat; K E Davies
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

3.  Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism?

Authors:  K Talbot; C P Ponting; A M Theodosiou; N R Rodrigues; R Surtees; R Mountford; K E Davies
Journal:  Hum Mol Genet       Date:  1997-03       Impact factor: 6.150

4.  PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy.

Authors:  G van der Steege; P M Grootscholten; P van der Vlies; T G Draaijers; J Osinga; J M Cobben; H Scheffer; C H Buys
Journal:  Lancet       Date:  1995-04-15       Impact factor: 79.321

5.  Genetic studies of acute infantile spinal muscular atrophy (SMA type I). An analysis of sex ratios, segregation ratios, and sex influence.

Authors:  J Pearn
Journal:  J Med Genet       Date:  1978-12       Impact factor: 6.318

6.  Essential role for the tudor domain of SMN in spliceosomal U snRNP assembly: implications for spinal muscular atrophy.

Authors:  D Bühler; V Raker; R Lührmann; U Fischer
Journal:  Hum Mol Genet       Date:  1999-12       Impact factor: 6.150

Review 7.  An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).

Authors:  B Wirth
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy: further delineation on the basis of SMN gene deletion findings.

Authors:  S Rudnik-Schöneborn; R Forkert; E Hahnen; B Wirth; K Zerres
Journal:  Neuropediatrics       Date:  1996-02       Impact factor: 1.947

9.  Diagnosis of spinal muscular atrophy in an SMN non-deletion patient using a quantitative PCR screen and mutation analysis.

Authors:  D W Parsons; P E McAndrew; P S Allinson; W D Parker; A H Burghes; T W Prior
Journal:  J Med Genet       Date:  1998-08       Impact factor: 6.318

10.  De novo and inherited deletions of the 5q13 region in spinal muscular atrophies.

Authors:  J Melki; S Lefebvre; L Burglen; P Burlet; O Clermont; P Millasseau; S Reboullet; B Bénichou; M Zeviani; D Le Paslier
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

View more
  45 in total

1.  Clinical utility gene card for: proximal spinal muscular atrophy.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

2.  Reorganization of Cajal bodies and nucleolar targeting of coilin in motor neurons of type I spinal muscular atrophy.

Authors:  Olga Tapia; Rocío Bengoechea; Ana Palanca; Rosa Arteaga; J Fernando Val-Bernal; Eduardo F Tizzano; María T Berciano; Miguel Lafarga
Journal:  Histochem Cell Biol       Date:  2012-02-01       Impact factor: 4.304

Review 3.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

4.  c.835-5T>G Variant in SMN1 Gene Causes Transcript Exclusion of Exon 7 and Spinal Muscular Atrophy.

Authors:  Shuang Wu; Yun-Lu Li; Ning-Yi Cheng; Chong Wang; En-Lin Dong; Ying-Qian Lu; Jin-Jing Li; Xin-Xin Guo; Xiang Lin; Lu-Lu Lai; Zhi-Wei Liu; Ning Wang; Wan-Jin Chen
Journal:  J Mol Neurosci       Date:  2018-05-24       Impact factor: 3.444

5.  Correlation of PLS3 expression with disease severity in children with spinal muscular atrophy.

Authors:  Cao Yanyan; Qu Yujin; Bai Jinli; Jin Yuwei; Wang Hong; Song Fang
Journal:  J Hum Genet       Date:  2013-10-31       Impact factor: 3.172

6.  Clinical utility gene card for: Proximal spinal muscular atrophy (SMA) - update 2015.

Authors:  Sabine Rudnik-Schöneborn; Thomas Eggermann; Wolfram Kress; Henny H Lemmink; Jan-Maarten Cobben; Klaus Zerres
Journal:  Eur J Hum Genet       Date:  2015-05-20       Impact factor: 4.246

Review 7.  Spliceosomal small nuclear ribonucleoprotein biogenesis defects and motor neuron selectivity in spinal muscular atrophy.

Authors:  Eileen Workman; Stephen J Kolb; Daniel J Battle
Journal:  Brain Res       Date:  2012-02-28       Impact factor: 3.252

8.  Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling.

Authors:  Laura Alías; Sara Bernal; Maite Calucho; Elisabeth Martínez; Francesca March; Pia Gallano; Pablo Fuentes-Prior; Anna Abuli; Clara Serra-Juhe; Eduardo F Tizzano
Journal:  Eur J Hum Genet       Date:  2018-06-14       Impact factor: 4.246

9.  Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.

Authors:  Julia Schreml; Markus Riessland; Mario Paterno; Lutz Garbes; Kristina Roßbach; Bastian Ackermann; Jan Krämer; Eilidh Somers; Simon H Parson; Raoul Heller; Albrecht Berkessel; Anja Sterner-Kock; Brunhilde Wirth
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

Review 10.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.